Retatrutide vs Orforglipron: Injectable Triple Agonist vs Oral GLP-1
Retatrutide and orforglipron are both made by Eli Lilly, but they represent completely different approaches to obesity treatment. Retatrutide is an injectable triple agonist targeting three receptors for maximum weight loss. Orforglipron is an oral daily pill targeting one receptor for maximum convenience — no needles, no fasting, no food restrictions.
The trade-off is clear: retatrutide produces nearly 2.5 times more weight loss than orforglipron, but orforglipron eliminates the injection barrier that deters many patients from starting treatment.
Side-by-Side Comparison
| Retatrutide | Orforglipron | |
|---|---|---|
| Delivery | Once-weekly injection | Once-daily oral pill |
| Molecule type | Peptide (injectable) | Small molecule, non-peptide (oral) |
| Receptors | GLP-1 + GIP + Glucagon (triple agonist) | GLP-1 only (single agonist) |
| Max weight loss | -28.7% at 68 weeks (TRIUMPH-4) | -12.4% at 72 weeks (ATTAIN-1) |
| Max dose | 12 mg weekly | 36 mg daily |
| Food restrictions | None | None (unlike oral semaglutide/Rybelsus) |
| FDA timeline | Expected ~2027 | Expected March 2026 |
| GI discontinuation | 12-18% | 5.3-10.3% |
| Unique signal | Dysesthesia (8.8-20.9%) | None beyond GI class effects |
| Projected 2031 sales | $30 billion | $16 billion |
How the Mechanisms Differ
Orforglipron: One Receptor, Oral Delivery
Orforglipron (LY3502970) is a non-peptide, small-molecule GLP-1 receptor agonist. Unlike injectable GLP-1 drugs (which are peptides that would be destroyed by stomach acid), orforglipron is a small molecule that acts as an allosteric agonist — it binds within a transmembrane pocket on the GLP-1 receptor, distinct from where the natural GLP-1 hormone binds, and stabilizes an active receptor conformation.
Because it is a small molecule, orforglipron is:
- Chemically stable in stomach acid — no special coating or absorption enhancers needed
- Resistant to digestive enzymes (DPP-4 and proteases) that would destroy peptide drugs
- Taken any time of day without fasting or food/water restrictions
This is a significant advantage over oral semaglutide (Rybelsus), which requires 30 minutes of fasting with minimal water.
Retatrutide: Three Receptors, Maximum Efficacy
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. The additional GIP and glucagon pathways drive substantially more weight loss. The glucagon component in particular increases resting energy expenditure through thermogenesis — your body burns more calories at rest — and promotes liver fat oxidation.
For details on each receptor, see What Is Retatrutide (GLP-3)?.
Weight Loss Comparison
| Drug | Trial | Duration | Max Weight Loss |
|---|---|---|---|
| Retatrutide 12 mg | TRIUMPH-4 (Phase 3) | 68 weeks | -28.7% |
| Orforglipron 36 mg | ATTAIN-1 (Phase 3) | 72 weeks | -12.4% |
| Orforglipron 36 mg (T2D) | ATTAIN-2 (Phase 3) | 72 weeks | -10.5% |
Retatrutide's weight loss is approximately 2.3 times greater than orforglipron at comparable timepoints. This is consistent with the pattern seen across GLP-1 drugs: single agonists produce ~12-17% weight loss, dual agonists ~22%, and the triple agonist ~29%.
Weight Loss Thresholds (Orforglipron, ATTAIN-1)
| Threshold | Orforglipron 36 mg | Placebo |
|---|---|---|
| Lost at least 10% | 59.6% | — |
| Lost at least 15% | 39.6% | — |
Switching Between the Two
Lilly's ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable incretins (semaglutide or tirzepatide) to oral orforglipron maintained most of their prior weight loss. Average differences were only 0.9 kg from semaglutide and 5.0 kg from tirzepatide over 52 weeks. This suggests orforglipron could serve as a maintenance option after achieving weight loss on injectable drugs — though switching from retatrutide to orforglipron has not been studied.
Side Effects and Tolerability
| Retatrutide | Orforglipron | |
|---|---|---|
| Most common | Nausea, diarrhea, constipation, vomiting | Diarrhea, nausea, constipation, vomiting, dyspepsia |
| Severity | Mostly mild-moderate | Mostly mild-moderate |
| Discontinuation (AEs) | 12-18% | 5.3-10.3% (vs 2.7% placebo) |
| Unique signal | Dysesthesia (tingling/burning) in 8.8-20.9% | None beyond GI class effects |
| Notable absence | — | No pancreatitis, retinal, or optic signals |
Orforglipron has a lower discontinuation rate than retatrutide, and GI side effects typically improve within 4-8 weeks during dose escalation. Orforglipron's Phase 3 data notably showed no signals for pancreatitis, retinal detachment, or ischemic optic neuropathy.
FDA Timeline
| Milestone | Orforglipron | Retatrutide |
|---|---|---|
| NDA submitted | Late 2025 (obesity) | Not yet filed |
| FDA review | Granted National Priority Voucher | Standard review expected |
| Expected approval | March 2026 | ~2027 |
| Diabetes filing | Planned 2026 | Pending TRANSCEND data |
Orforglipron received the FDA Commissioner's National Priority Voucher, which could shorten review from the standard 10-12 months to potentially 1-2 months. This would make it the second oral GLP-1 approved for obesity (after Novo Nordisk's oral Wegovy).
Lilly's Portfolio Strategy
Eli Lilly is developing both drugs because they serve different patient needs:
- Orforglipron — for patients who prefer or need oral therapy, needle-phobic patients, maintenance therapy after initial injectable weight loss, or patients who need moderate weight loss (~12%)
- Retatrutide — for patients seeking maximum weight loss, those with comorbidities like fatty liver disease or knee osteoarthritis where the glucagon mechanism adds specific benefit
The two drugs are complementary, not competing. Analysts project combined 2031 sales of ~$46 billion ($30B retatrutide + $16B orforglipron).
Frequently Asked Questions
Is retatrutide better than orforglipron?
Retatrutide produces substantially more weight loss (-28.7% vs -12.4%). However, orforglipron offers the convenience of an oral pill with no injections. The best choice depends on individual goals, needle tolerance, and medical needs. Both drugs are still investigational.
Why does orforglipron produce less weight loss?
Orforglipron activates only one receptor (GLP-1), while retatrutide activates three (GLP-1, GIP, glucagon). The additional receptors drive significantly more weight loss. This follows the consistent pattern: more receptor targets correlate with greater weight loss across all incretin drugs studied.
Can I take orforglipron as a pill while waiting for retatrutide?
If orforglipron is approved (expected March 2026), it could be an option while waiting for retatrutide (~2027). Discuss this with your doctor. The ATTAIN-MAINTAIN trial suggests that switching between oral and injectable incretins is feasible.
Will Lilly make a retatrutide pill?
There is no announced plan for an oral retatrutide. Retatrutide is a peptide that requires injection. Developing an oral version would face significant technical challenges due to its large molecular size and triple receptor binding requirements. See Retatrutide Pill vs Injection.
Sources
- Eli Lilly. (2025). ATTAIN-1 Phase 3 results. Press release.
- Wharton, S., et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM. DOI: 10.1056/NEJMoa2511774
- Eli Lilly. (2025). ATTAIN-MAINTAIN results. Press release.
- Eli Lilly. (2025). TRIUMPH-4 results. Press release.
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Both retatrutide and orforglipron are investigational drugs that have not been approved by the FDA.
Do not use this information to make decisions about your health without consulting a qualified healthcare provider. If you are considering weight loss medication, talk to your doctor about currently approved options.
This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.
Sources
- ATTAIN-1 trial (orforglipron)
NEJM
- TRIUMPH-4 results
Eli Lilly
Related reading
Retatrutide Pill vs Injection: Is There an Oral Formulation?
Retatrutide is injection-only. Here's why there's no pill, how the injection works, and how oral GLP-1 alternatives compare.
Retatrutide vs Mounjaro vs Ozempic
How the three generations of weight loss drugs compare — single, dual, and triple agonists.
What Is Retatrutide (GLP-3)?
The world's first triple agonist weight loss drug — how it works, what the trials show, and why people call it GLP-3.